Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Bryce, M.
space
  arrow  Kotler, M. N.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REVIEW

Evolving Indications for Permanent Pacemakers

right arrow Miguel Bryce, MD; Scott R. Spielman, MD; Allan M. Greenspan, MD; and Morris N. Kotler, MD

19 June 2001 | Volume 134 Issue 12 | Pages 1130-1141

New indications for permanent cardiac pacing have been developed in recent years, with numerous studies demonstrating improved clinical outcomes in a variety of disorders. Because hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, heart failure, neurocardiogenic syncope, and atrial fibrillation are common conditions, every clinician should be aware of evolving alternative therapies for them.

Observational studies in patients with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant left ventricular outflow gradient at rest suggest that cardiac pacing may result in symptomatic and hemodynamic improvement. Clinical trials have not shown conclusive evidence regarding the long-term benefit from pacing in these patients, and it is unclear whether pacing will be a preferred treatment option. Preliminary data suggest that pacing is a viable adjunctive therapeutic approach for improving symptoms in patients with dilated cardiomyopathy and heart failure. Mortality benefit has yet to be established, but it is to be hoped that ongoing randomized clinical trials will provide definitive information on that issue. Patients with refractory neurocardiogenic syncope or those who are intolerant of medical treatment may benefit from pacing therapies, especially those that use rate-drop sensor algorithms. Biatrial pacing has emerged as a technique that resynchronizes atrial electrical activity and has been shown to prevent atrial fibrillation. Multisite atrial pacing for the prevention of atrial fibrillation is considered investigational but seems promising. Newer indications for pacing are expected to result in improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy and heart failure, neurocardiogenic syncope, and the prevention of atrial fibrillation.

Author and Article Information
space

From Albert Einstein Medical Center, Philadelphia, Pennsylvania.

Requests for Single Reprints: Morris N. Kotler, MD, Albert Einstein Medical Center, Division of Cardiovascular Diseases, 5401 Old York Road, Klein Building, Suite 363, Philadelphia, PA 19141.

Current Author Addresses: Drs. Bryce and Kotler: Albert Einstein Medical Center, Division of Cardiovascular Diseases, 5401 Old York Road, Klein Building, Suite 363, Philadelphia, PA 19141.

Drs. Spielman and Greenspan: Albert Einstein Medical Center, Division of Cardiovascular Diseases, 5501 Old York Road, EPS Offices, Levy 3 East, Philadelphia, PA 19141.




This article has been cited by other articles:


Home page
JAMAHome page
B. J. Maron
Hypertrophic Cardiomyopathy: A Systematic Review
JAMA, March 13, 2002; 287(10): 1308 - 1320.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2001 by the American College of Physicians.